Inovio Pharmaceuticals IncNASDAQ:INO
- LAST PRICE9.9950
- TODAY'S CHANGE (%)0.2250 (2.3030%)
- Bid / Lots9.9700/ 4
- Ask / Lots10.0400/ 1
- Open / Previous Close9.8100 / 9.7700
- Day Range
- 52 Week Range
- Volume81,244
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INO |
|---|---|---|
| 09:32 ET | 4815 | 9.81 |
| 09:34 ET | 4057 | 9.775 |
| 09:36 ET | 4718 | 9.855 |
| 09:38 ET | 2949 | 9.99 |
| 09:41 ET | 1556 | 10.02 |
| 09:43 ET | 1227 | 10.05 |
| 09:45 ET | 1543 | 10.08 |
| 09:48 ET | 1586 | 10.05 |
| 09:50 ET | 1127 | 10 |
| 09:54 ET | 255 | 9.995 |
| 09:56 ET | 2950 | 9.93 |
| 09:57 ET | 926 | 9.88 |
| 09:59 ET | 105 | 9.8566 |
| 10:01 ET | 466 | 9.835 |
| 10:06 ET | 109 | 9.8 |
| 10:08 ET | 163 | 9.7253 |
| 10:10 ET | 6504 | 9.82 |
| 10:12 ET | 734 | 9.85 |
| 10:14 ET | 1200 | 9.91 |
| 10:15 ET | 1662 | 9.99 |
| 10:17 ET | 4355 | 10.0501 |
| 10:21 ET | 1024 | 10.14 |
| 10:24 ET | 910 | 10.2399 |
| 10:26 ET | 1882 | 10.13 |
| 10:28 ET | 180 | 10.125 |
| 10:30 ET | 2382 | 10.165 |
| 10:32 ET | 294 | 10.142 |
| 10:35 ET | 2249 | 10.04 |
| 10:37 ET | 800 | 10.055 |
| 10:39 ET | 4135 | 10.08 |
| 10:42 ET | 436 | 10.08 |
| 10:44 ET | 5000 | 10.0355 |
| 10:46 ET | 263 | 10.05 |
| 10:48 ET | 365 | 9.995 |
May 14, 2024
DJ Inovio Pharma Initiated at Overweight by Stephens & Co., from 6:11AM ET on Tuesday May 14, 2024 by Dow Jones
6:11AM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
*DJ Inovio Pharma 1Q Loss/Shr $1.31 >INO, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow JonesINOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones
May 1, 2024
Press Release: INOVIO Reports Inducement Grants Under Inducement Plan, from 8:01AM ET on Wednesday May 01, 2024 by Dow Jones
8:01AM ET on Wednesday May 01, 2024 by Dow JonesINOVIO Reports Inducement Grants Under Inducement Plan, from 8:00AM ET on Wednesday May 01, 2024 by Dow Jones
8:00AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inovio Pharmaceuticals Inc | 253.1M | -1.8x | --- |
Monte Rosa Therapeutics Inc | 250.7M | -1.6x | --- |
Candel Therapeutics Inc | 256.4M | -6.9x | --- |
Rani Therapeutics Holdings Inc | 258.2M | -4.2x | --- |
Century Therapeutics Inc | 256.2M | -1.4x | --- |
Actinium Pharmaceuticals Inc | 241.5M | -4.8x | --- |
Company Information
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Contact Information
- Headquarters
- 6769 Mesa Ridge Rd.SAN DIEGO, CA, United States 92121
- Phone
- 858-410-3134
- Fax
- 858-404-1392
Executives
- Independent Chairman of the Board
- Simon Benito
- President, Chief Executive Officer, Director
- Jacqueline Shea
- Non-Executive Independent Vice Chairman of the Board
- Jay Shepard
- Chief Financial Officer
- Peter Kies
- Chief Scientific Officer
- Laurent Humeau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $253.1M |
|---|---|
Revenue (TTM) | $717.1K |
Shares Outstanding | 25.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-5.54 |
Book Value | $5.15 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 353.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -18,334.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
